Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : WR, LB and Friends. NO HYPESTERS OR SCAMMERS -- Ignore unavailable to you. Want to Upgrade?

To: Wayne Rumball who wrote (7457)	4/15/1999 12:48:00 PM
From: dowen	Respond to of 13776

I'll definitely have that ICQ out ASAP. (EOM)

To: Wayne Rumball who wrote (7457)	4/15/1999 1:20:00 PM
From: LANCE B	Read Replies (2) \| Respond to of 13776

COII- picked up on news.. .PR NEWSWIRE) TMI Receives Approval from FDA to File 'Modular Pre-Market A TMI Receives Approval from FDA to File 'Modular Pre-Market Approval Application' for its Thermal Breast Imaging System OGDEN, Utah, April 15 /PRNewswire/ -- Computerized Thermal Imaging, Inc. (OTC Bulletin Board: COII) (CTI) announced today that its subsidiary, Thermal Medical Imaging, Inc. (TMI) has received approval from the FDA to file a Modular Pre-Market Approval for its Thermal Breast Imaging System. "I'm excited to begin the formal FDA approval process. Use of the Modular PMA process allows us to begin submitting information and start the dialog necessary to address the many details of the FDA approval process much earlier than would otherwise be possible," said David Packer, President of TMI. The FDA's "Modular Pre-Market Approval Application" has been recently adopted by the Agency in order to facilitate the review and approval process of new medical devices. The essence of a modular concept for data development, submission, review, and closure is to break the contents of a PMA into well-delineated components and to have reports of each component submitted as soon as the sponsor has performed the testing and analyses. This would a allow more rapid closure when the last components are submitted because much of the review work will already have been completed. TMI is seeking approval for the Thermal Breast Imaging System as an adjunctive diagnostic test to mammogram and clinical examination for the detection of breast cancer. The system is currently undergoing multi-center clinical trials to test its efficacy in differentiating benign from malignant breast abnormalities. The system uses a sophisticated heat sensitive camera to record thermal images of breast tissue. These images are then processed with a proprietary computer algorithm designed to recognize the distinct heat signatures of benign and malignant tissue. The test is simple, painless and requires no exposure to radiation or breast compression. The worldwide market for safe and effective adjunctive test for breast cancer could reach $2 billion within a few years of market introduction. Industry sources indicate that a cost-effective examination with the demonstrated ability to correctly identify malignant lesions would rapidly gain market acceptance, as it would save the healthcare system millions of dollars in benign biopsy costs. An average breast biopsy currently costs $2,000, with 70%-80% of breast biopsies yielding benign results. Computerized Thermal Imaging, Inc. develops and deploys thermal imaging and associated technologies for use in the enhancement of medical screening, diagnosis and patient management. More information about CTI can be found on the Internet at www.cti-net.com or by calling CTI Public Affairs at (801) 776-4700. Except for historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In addition to the factors set forth above, other important factors that could cause actual results to differ materially include, but are not limited to technical risks associated with new technology development, government regulatory approvals or continued working capital. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings. Copies of these filings may be obtained by contacting the Company or the SEC. SOURCE Computerized Thermal Imaging, Inc. -0- 04/15/99 /CONTACT: Jeff Lloyd or Tom J. Ekman of Sitrick And Company, 310-788-2850, for Computerized Thermal Imaging, Inc./ /Company News On-Call: prnewswire.com or fax, 800-758-5804, ext. 566035/ /Web site: cti-net.com (COII) CO: Computerized Thermal Imaging, Inc.; Thermal Medical Imaging, Inc. ST: Utah IN: MTC HEA SU: PDT